ArticleFrontiers in oncology2026
Study protocol: analysis of gene expression profiles in peripheral blood and tumor tissue of Colombian patients diagnosed with epithelial ovarian cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular characterization of epithelial ovarian cancer has been conducted predominantly in populations of European ancestry, leaving Latin American populations significantly underrepresented. Colombian patients, characterized by a unique admixture of Amerindian, European, and African ancestries, lack integrated genomic and transcriptomic studies. This study aims to characterize germline variants and gene expression profiles in peripheral blood and tumor tissue from Colombian patients with epithelial ovarian cancer, to identify clinically relevant molecular alterations. Methods: This is a single-center, prospective, cross-sectional analytical study that will include 30 Colombian women diagnosed with epithelial ovarian cancer (stages I-III) and 30 healthy controls, recruited at Hospital Universitario Mayor Méderi in Bogotá. The study will be conducted in three phases (1): standardized collection of paired tumor tissue and peripheral blood samples (2); germline genetic profiling using a 106-gene hereditary cancer next-generation sequencing panel, with variant classification according to international guidelines; and (3) transcriptomic analysis through RNA sequencing in both tissue and blood samples. Differential gene expressions, functional enrichment analysis, tumor microenvironment characterization, and integrated germline-transcriptomic analyses will be performed. Ethical approval was obtained from the Ethics Committee of Universidad del Rosario, and written informed consent will be obtained from all participants before enrollment. Discussion: This study will generate the first integrated germline and transcriptomic dataset for epithelial ovarian cancer in a Colombian population. The identification of clinically relevant genetic variants and expression patterns may contribute to improved molecular stratification and support the development of precision oncology approaches. Additionally, this work aims to provide foundational evidence for the implementation of population-specific biomarkers and to reduce existing disparities in cancer genomic research in Latin America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.